NCT00042666 - A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas. | Biotech Hunter

Enrollment

55

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG

LY317615

500 mg, oral, QD, up to six 28 day cycles

Trial Locations (3)

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Royal Oak

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester